|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.61 USD | +3.10% |
|
-2.45% | -18.68% |
| 06-11 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| 06-11 | Race to launch weight-loss pill heats up as Novo wins UK approval | RE |
| Market Cap | 3.22B 2.78B 2.56B 2.4B 4.5B 308B 4.57B 30.38B 11.8B 149B 12.09B 11.83B 516B | P/E Ratio 2026 * |
-5.77x | P/E Ratio 2027 * | -6x |
|---|---|---|---|---|---|
| Enterprise Value | 2.69B 2.33B 2.14B 2.01B 3.76B 258B 3.82B 25.4B 9.87B 124B 10.11B 9.89B 431B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
97.21% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Viking Therapeutics, Inc.
| 1 day | -0.14% | ||
| 1 week | -2.45% | ||
| Current month | -12.61% | ||
| 1 month | -8.68% | ||
| 3 months | -17.46% | ||
| 6 months | -23.77% | ||
| Current year | -18.68% |
| 1 week | 27.16 |  | 30.1 |
| 1 month | 27.16 | | 33.16 |
| Current year | 25.77 | | 37.5 |
| 1 year | 22.96 | | 43.15 |
| 3 years | 8.28 | | 99.41 |
| 5 years | 2.02 | | 99.41 |
| 10 years | 0.88 | | 99.41 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brian Lian
CEO | Chief Executive Officer | 60 | 23/09/2012 |
Gregory Zante
DFI | Director of Finance/CFO | 55 | 03/01/2021 |
Tavette Neskorik
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Lawson Macartney
CHM | Chairman | 68 | 30/04/2015 |
Brian Lian
CHM | Chairman | 60 | 23/09/2012 |
Matthew Foehr
BRD | Director/Board Member | 53 | 30/04/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-31 | Free | Chief Medical Officer | 190,000 | 0.1636% | ||
| 03-09 | Buy | Executive/Senior Manager | 4,475 | 0.0039% | ||
| 01-11 | Free | Executive/Senior Manager | 180,000 | 0.1592% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.10% | -2.45% | -1.82% | +17.88% | 3.22B | |
| +1.65% | +11.53% | +52.68% | +112.78% | 54.82B | |
| +0.03% | -1.80% | +49.57% | +43.94% | 43.27B | |
| +3.93% | +1.23% | -16.23% | -18.04% | 21.79B | |
| +5.27% | -6.87% | +6.37% | +388.48% | 19.92B | |
| +0.81% | -8.38% | +12.77% | -33.24% | 15.67B | |
| +0.53% | +6.07% | +8.13% | -39.59% | 15.26B | |
| +1.75% | +3.68% | +25.82% | +178.65% | 13.22B | |
| -5.27% | +3.89% | +90.88% | +208.02% | 11.58B | |
| -1.74% | -1.05% | +12.88% | - | 11.94B | |
| Average | +0.34% | -1.06% | +24.10% | +95.43% | 21.07B | |
| Weighted average by Cap. | +0.80% | +1.06% | +31.67% | +96.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -563M -486M -447M -419M -786M -53.91B -799M -5.31B -2.06B -26.02B -2.11B -2.07B -90.08B | -587M -507M -467M -438M -820M -56.24B -833M -5.54B -2.15B -27.15B -2.21B -2.16B -93.99B |
| Net Debt | -528M -456M -420M -393M -737M -50.56B -749M -4.98B -1.93B -24.4B -1.98B -1.94B -84.48B | -523M -452M -416M -390M -731M -50.12B -742M -4.94B -1.92B -24.19B -1.96B -1.92B -83.75B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/06/26 | 28.61 $ | +3.10% | 2,660,328 |
| 10/06/26 | 27.75 $ | -5.06% | 2,739,117 |
| 09/06/26 | 29.23 $ | -0.03% | 2,252,097 |
| 08/06/26 | 29.24 $ | +2.78% | 2,096,389 |
| 05/06/26 | 28.45 $ | -4.47% | 2,738,744 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VKTX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition